α-Emitting radionuclides have been approved for cancer treatment since 2013, with
increasing degrees of success. Despite this clinical utility, little is known regarding the …

Despite the consensus around the clinical potential of the α-emitting radionuclide astatine-
211 (211At), there are only a limited number of research facilities that work with this nuclide …

Astatine-211 (211At) has physical properties that make it one of the top candidates for use
as a radiation source for alpha particle-based radionuclide therapy, also referred as targeted …

B7-H3 belongs to the B7 family of immune checkpoint proteins, which are important
regulators of the adaptive immune response and emerging key players in human cancer. B7 …

Eliminating microscopic residual disease with α-particle radiation is theoretically appealing.
After extensive preclinical work with α-particle–emitting 211At, we performed a phase I trial …

Introduction We recently validated monoclonal antibody (mAb) 376.96 as an effective carrier
for targeted α-particle radioimmunotherapy (RIT) with 212 Pb in ovarian cancer mouse …

Introduction Novel therapies that effectively kill both differentiated cancer cells and cancer
initiating cells (CICs), which are implicated in causing chemotherapy-resistance and disease …

Background To characterize the expression of the membrane transporter NaPi2b and
antigen targeted by the MX35 antibody in ovarian tumor samples. The current interest to …

Introduction Antibodies labeled with alpha-emitter astatine-211 have previously shown
effective in intraperitoneal (ip) treatments of ovarian cancer. In the present work we explore …

Targeted alpha therapy of disseminated cancer is an emerging technique where astatine-
211 is one of the most promising candidate nuclides. Although astatine has been known for …